Business Wire

ORAL-B

Share
Oral-B® Announces its Partnership with the iADH (International Association of Disability and Oral Health) to Help Make Oral Care More Accessible and for All

Oral-B, the leading innovator in oral health, announces partnership with the International Association of Disability and Oral Health (iADH) as part of the brand’s drive to make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005621/en/

Approximately 166 million people in Europe are affected by a disability in some way and recent research reveals that a third (1/3) of those experience gum issues due to struggles with maintaining their oral health1 . Oral-B is on a mission to ensure that everybody has an equitable oral care experience - whether that be at the dentist practice, easily accessible and personalised tips and tricks or with the products that are used at home to maintain oral health.

Benjamin Binot, P&G Europe Oral Care Senior Vice President says: “As the leading innovator in oral health for over 70 years and the #1 dentist recommended brand, we recognise the importance of making oral care accessible to all – and continuously listen to people's experiences with disabilities to understand how we can help them. Through this work, we have learned that oral health care struggles amongst this audience are most common because many haven’t been taught the skills they need to brush their teeth effectively, they experience a sense of inevitability about their teeth deteriorating and may be especially anxious in the dentist’s chair. As a brand, we recognize our responsibility to help ensure that oral care is accessible to all and we are proud to partner with the iADH to work to improve the experience for people living with disabilities.”

The first step of this partnership is to co-create a ‘Positive Practices’ training program designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients.

Alison Dougall, iADH President says; “We are delighted to be working alongside Oral-B to address the significant oral health inequalities experienced by people with disabilities in Europe, through innovation, education, research and advocacy. By working together, we aim to make a positive difference to the oral care experience for people living with visible and nonvisible disabilities.

iADH exists to improve desired oral health outcomes for people with disabilities and Oral-B exists to create the best oral care outcomes by providing the most rewarding and enjoyable oral care experiences for everyone, everyday – given our shared values, it felt like a very natural fit when Oral-B approached us to come together in partnership”

The brand will also be present at this year’s Biennial iADH Congress 2022 in Paris to learn from the global members, who will be sharing their knowledge and experience to improve oral health outcomes for people with disabilities in a KOL workshop hosted by Oral-B. The findings gathered from the workshop will help to inform Positive Practices and ensure that the training programme is underpinned by insight to deliver the best outcome for change.

-ENDS-

About Oral-B

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.

About The iADH (International Association of Disability and Oral Health)

The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability

1 The Oral Health & Disability European Study, March 2022, Oral-B

For more information, please visit: https://www.oralb.co.uk/en-gb

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye